UT-MD Anderson Cancer Center: AACR - First-in-class Covalent Werner Helicase Inhibitor Shows Clinical Proof-of-concept in Phase I Trial
April 28, 2025
April 28, 2025
HOUSTON, Texas, April 28 -- The University of Texas MD Anderson Cancer Center issued the following news release:
* * *
AACR: First-in-class covalent Werner helicase inhibitor shows clinical proof-of-concept in Phase I trial
* RO7589831, a new drug from Roche, is first in a new class of drugs called Werner helicase inhibitors
* Drug works similarly to other DNA damage repair inhibitors, such as PARP inhibitors
* This class of drugs . . .
* * *
AACR: First-in-class covalent Werner helicase inhibitor shows clinical proof-of-concept in Phase I trial
* RO7589831, a new drug from Roche, is first in a new class of drugs called Werner helicase inhibitors
* Drug works similarly to other DNA damage repair inhibitors, such as PARP inhibitors
* This class of drugs . . .